Vitamin D deficiency in critically ill COVID-19 ARDS patients.
Acute respiratory distress syndrome
Critical care
Immune response
Nutrient supplementation
Vitamin D
Journal
Clinical nutrition (Edinburgh, Scotland)
ISSN: 1532-1983
Titre abrégé: Clin Nutr
Pays: England
ID NLM: 8309603
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
15
12
2020
revised:
16
02
2021
accepted:
01
03
2021
pubmed:
23
3
2021
medline:
7
12
2022
entrez:
22
3
2021
Statut:
ppublish
Résumé
Vitamin D's pleiotropic effects include immune modulation, and its supplementation has been shown to prevent respiratory tract infections. The effectivity of vitamin D as a therapeutic intervention in critical illness remains less defined. The current study analyzed clinical and immunologic effects of vitamin D levels in patients suffering from coronavirus disease 2019 (COVID-19) induced acute respiratory distress syndrome (ARDS). This was a single-center retrospective study in patients receiving intensive care with a confirmed SARS-CoV-2 infection and COVID-19 ARDS. 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D serum levels, pro- and anti-inflammatory cytokines and immune cell subsets were measured on admission as well as after 10-15 days. Clinical parameters were extracted from the patient data management system. Standard operating procedures included the daily administration of vitamin D A total of 39 patients with COVID-19 ARDS were eligible, of which 26 were included in this study as data on vitamin D status was available. 96% suffered from severe COVID-19 ARDS. All patients without prior vitamin D supplementation (n = 22) had deficient serum levels of 25-hydroxyvitamin D. Vitamin D supplementation resulted in higher serum levels of 25-hydroxyvitamin D but not did not increase 1,25-dihydroxyvitamin D levels after 10-15 days. Clinical parameters did not differ between patients with sufficient or deficient levels of 25-hydroxyvitamin D. Only circulating plasmablasts were higher in patients with 25-hydroxyvitamin D levels ≥30 ng/ml (p = 0.029). Patients with 1,25-dihydroxyvitamin D levels below 20 pg/ml required longer mechanical ventilation (p = 0.045) and had a worse acute physiology and chronic health evaluation (APACHE) II score (p = 0.048). The vast majority of COVID-19 ARDS patients had vitamin D deficiency. 25-hydroxyvitamin D status was not related to changes in clinical course, whereas low levels of 1,25-dihydroxyvitamin D were associated with prolonged mechanical ventilation and a worse APACHE II score.
Sections du résumé
BACKGROUND & AIMS
Vitamin D's pleiotropic effects include immune modulation, and its supplementation has been shown to prevent respiratory tract infections. The effectivity of vitamin D as a therapeutic intervention in critical illness remains less defined. The current study analyzed clinical and immunologic effects of vitamin D levels in patients suffering from coronavirus disease 2019 (COVID-19) induced acute respiratory distress syndrome (ARDS).
METHODS
This was a single-center retrospective study in patients receiving intensive care with a confirmed SARS-CoV-2 infection and COVID-19 ARDS. 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D serum levels, pro- and anti-inflammatory cytokines and immune cell subsets were measured on admission as well as after 10-15 days. Clinical parameters were extracted from the patient data management system. Standard operating procedures included the daily administration of vitamin D
RESULTS
A total of 39 patients with COVID-19 ARDS were eligible, of which 26 were included in this study as data on vitamin D status was available. 96% suffered from severe COVID-19 ARDS. All patients without prior vitamin D supplementation (n = 22) had deficient serum levels of 25-hydroxyvitamin D. Vitamin D supplementation resulted in higher serum levels of 25-hydroxyvitamin D but not did not increase 1,25-dihydroxyvitamin D levels after 10-15 days. Clinical parameters did not differ between patients with sufficient or deficient levels of 25-hydroxyvitamin D. Only circulating plasmablasts were higher in patients with 25-hydroxyvitamin D levels ≥30 ng/ml (p = 0.029). Patients with 1,25-dihydroxyvitamin D levels below 20 pg/ml required longer mechanical ventilation (p = 0.045) and had a worse acute physiology and chronic health evaluation (APACHE) II score (p = 0.048).
CONCLUSION
The vast majority of COVID-19 ARDS patients had vitamin D deficiency. 25-hydroxyvitamin D status was not related to changes in clinical course, whereas low levels of 1,25-dihydroxyvitamin D were associated with prolonged mechanical ventilation and a worse APACHE II score.
Identifiants
pubmed: 33745749
pii: S0261-5614(21)00135-7
doi: 10.1016/j.clnu.2021.03.001
pmc: PMC7937427
pii:
doi:
Substances chimiques
Vitamin D
1406-16-2
Calcifediol
P6YZ13C99Q
Vitamins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3089-3095Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2021 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest None.
Références
Crit Care. 2017 Nov 23;21(1):287
pubmed: 29169388
JAMA. 2014 Oct 15;312(15):1520-30
pubmed: 25268295
Br J Nutr. 2011 Nov;106(9):1433-40
pubmed: 21736791
N Engl J Med. 2007 Jul 19;357(3):266-81
pubmed: 17634462
Biomed Res Int. 2018 May 22;2018:9276380
pubmed: 29951549
BMJ Open. 2020 Nov 19;10(11):e040402
pubmed: 33444201
N Engl J Med. 2019 Dec 26;381(26):2529-2540
pubmed: 31826336
Pediatrics. 2011 Jun;127(6):e1513-20
pubmed: 21555499
Clin Nutr. 2018 Aug;37(4):1238-1246
pubmed: 28549527
J Immunol. 2016 Apr 1;196(7):2965-72
pubmed: 26895836
J Public Health (Oxf). 2020 Aug 18;42(3):451-460
pubmed: 32556213
Sci Rep. 2019 May 6;9(1):6974
pubmed: 31061425
J Steroid Biochem Mol Biol. 2014 Oct;144 Pt A:138-45
pubmed: 24239505
Adv Nutr. 2012 Jul 01;3(4):517-25
pubmed: 22797987
Front Immunol. 2012 Apr 17;3:78
pubmed: 22566959
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30
pubmed: 21646368
Crit Care. 2014 Mar 24;18(2):R47
pubmed: 24661739
Clin Exp Immunol. 2010 Nov;162(2):271-9
pubmed: 20854328
PLoS One. 2014 Jul 10;9(7):e101180
pubmed: 25009977
Cytometry B Clin Cytom. 2008 Sep;74(5):261-71
pubmed: 18561200
Ann Intern Med. 2007 Oct 16;147(8):W163-94
pubmed: 17938389
Crit Care. 2019 Jun 4;23(1):200
pubmed: 31164148
Am J Respir Crit Care Med. 2014 Sep 1;190(5):533-41
pubmed: 25029202
Front Immunol. 2018 Mar 12;9:458
pubmed: 29593721
Antiviral Res. 2017 Jan;137:93-101
pubmed: 27838350
Clin Nutr. 2019 Dec;38(6):2756-2762
pubmed: 30583965
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
N Engl J Med. 2020 Apr 23;382(17):1669
pubmed: 32320582
Front Immunol. 2020 Apr 07;11:602
pubmed: 32318074
BMJ. 2017 Feb 15;356:i6583
pubmed: 28202713
N Engl J Med. 2020 Apr 23;382(17):1669-1670
pubmed: 32320583